Immunovant, Inc. is a high-risk pharmaceutical company based in the United States of America that specializes in developing treatments for autoimmune diseases. With an ESG score of 35.7, Immunovant is dedicated to creating products that target the neonatal Fc receptor to help patients live normal lives.